Aims: This study aimed to study the efficacy of tranexamic acid (TXA) for reduction of blood loss in femur surgery.

Methods: This study design was a prospective randomized controlled double-blind study, from March 25th, 2019 to September 24th, 2019. Fifty-six (56) patients aged from 18 to 45 years, that underwent femur surgery, classed American Society of anesthesiologist I status were randomized into 2 groups. The first group received TXA in 50 cc of normal saline (group TXA) compared to control group Control (group C), 38 patients received 50 cc normal saline alone. Statistical Analysis used: Pearson khi² test, the Fisher test and Student test with P Value Ë‚5%.

Results: Fifty-six (56) patients randomized in two groups (TXA and C) of 28 patients. Demographic, clinical and paraclinical characteristics were the same in the two groups (p=ns). The average age was 27.79 years in group TXA versus 29.64 years in group C(p=0.045). Comparative study between the 2 groups revealed significant decrease of estimated blood loss (p=0.045) as well as a significant gain of final hemoglobin rate (p=0.009). There was no significative difference for blood transfusion (p=0.11).

Conclusion: Tranexamic acid significantly decreases the blood loss in femur surgery and has a gain on the final hemoglobin.